Pacer Advisors’s BridgeBio Pharma BBIO Stock Holding History

Pacer Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51K	Buy	+684	New	+$47.9K	﹤0.01%	2034
2024 Q3	–	Sell	-1,545	Closed	-$39.1K	–	2576
2024 Q2	$39.1K	Buy	1,545 +72	+5%	+$1.97K	﹤0.01%	3277
2024 Q1	$45.5K	Buy	+1,473	New	+$50.1K	﹤0.01%	3204
2021 Q2	–	Sell	-1,103	Closed	-$68K	–	1423
2021 Q1	$68K	Sell	1,103 -1,044	-49%	-$68.3K	﹤0.01%	1386
2020 Q4	$153K	Sell	2,147 -1,518	-41%	-$73.2K	﹤0.01%	1277
2020 Q3	$138K	Buy	+3,665	New	+$115K	﹤0.01%	1220

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Pacer Advisors's BBIO Position: Q2 2026 in Review

Pacer Advisors opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 684 shares worth $51K. The stake represents ﹤0.01% of the portfolio and ranks #2034 among its holdings. This is a return to the name: Pacer Advisors previously reported a position in BBIO as recently as Q2 2024.

Pacer Advisors first reported a position in BBIO in Q3 2020 and has held it in 6 quarters since. The position peaked at $153K in Q4 2020. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Pacer Advisors held 684 shares of BridgeBio Pharma worth $51K as of Q2 2026.
BridgeBio Pharma was a new Pacer Advisors position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Pacer Advisors's portfolio in Q2 2026, its #2034 holding.
Pacer Advisors first reported a position in BridgeBio Pharma in Q3 2020 and has held it in 6 quarters since.
Pacer Advisors's BridgeBio Pharma position peaked at $153K in Q4 2020.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.